



Clinical trial results: Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS) – Optional Blood Sample Collection Sub-study.

Summary

EudraCT number	2013-004090-28
Trial protocol	IT
Global end of trial date	30 April 2015

Results information

Result version number	v1 (current)
This version publication date	14 May 2016
First version publication date	14 May 2016
Summary attachment (see zip file)	B3461049 - Public Disclosure Synopsis (B3461049 Public Disclosure Synopsis_final.pdf)

Trial information

Trial identification

Sponsor protocol code	B3461049 (Fx-R-001-S1)
-----------------------	------------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 April 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 April 2015
Global end of trial reached?	Yes
Global end of trial date	30 April 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of this study was to collect blood samples planned to assist in the development and validation of a biomarker assay for transthyretin (TTR) amyloidoses.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 August 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 5
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Mexico: 5
Country: Number of subjects enrolled	Portugal: 15
Country: Number of subjects enrolled	United States: 2
Country: Number of subjects enrolled	Italy: 2
Worldwide total number of subjects	32
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	29
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This sub study of THAOS was a protocol to collect blood samples from enrolled subjects who had Val30Met, Glu89Gln, Phe64Leu, Thr60Ala, Ser50Arg, Ile107Val, Val20Ile, Ile68Leu, Val122Ile mutation, symptomatic ATTR disease, not treated with any medication which stabilizes or reduces the concentration of TTR, TTR monomer or oligomer in blood.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Entire Study Population
------------------	-------------------------

Arm description:

Subject who had symptomatic transthyretin amyloidosis (ATTR) disease with documented Val30Met, Glu89Gln, Phe64Leu, Thr60Ala, Ser50Arg, Ile107Val, Val20Ile, Ile68Leu, or Val122Ile mutation in the TTR protein and were a part of THAOS were enrolled into this sub-study.

Arm type	Blood Sample Collection Substudy
Investigational medicinal product name	None
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Unknown use

Dosage and administration details:

No investigational medicinal product was administered in this study.

Number of subjects in period 1	Entire Study Population
Started	32
Completed	32

Baseline characteristics

Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Study	Total	
Number of subjects	32	32	
Age categorical Units: Subjects			
Adults (18-64 years)	29	29	
From 65-84 years	3	3	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	49.23		
standard deviation	± 14.3	-	
Gender categorical Units: Subjects			
Female	20	20	
Male	12	12	

End points

End points reporting groups

Reporting group title	Entire Study Population
Reporting group description: Subject who had symptomatic transthyretin amyloidosis (ATTR) disease with documented Val30Met, Glu89Gln, Phe64Leu, Thr60Ala, Ser50Arg, Ile107Val, Val20Ile, Ile68Leu, or Val122Ile mutation in the TTR protein and were a part of THAOS were enrolled into this sub-study.	

Primary: Number of Subjects With Their Blood Samples Collected To Assist in Development and Validation of Biomarker Assay for Transthyretin (TTR) Amyloidoses

End point title	Number of Subjects With Their Blood Samples Collected To Assist in Development and Validation of Biomarker Assay for Transthyretin (TTR) Amyloidoses ^[1]
-----------------	---

End point description:

Blood was collected from subjects who had the following mutations in the TTR protein: Val30Met, Glu89Gln, Thr60Ala, Ser50Arg, Val20Ile, and Val122Ile, had symptomatic ATTR disease, and had not been treated with any medication or treatment which stabilizes or reduces the concentration of TTR, TTR monomer, or TTR oligomer in the blood. These blood samples were collected to assist in the development and validation of a biomarker assay for TTR amyloidosis. Entire study population was analyzed.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to 268 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or conducted for this substudy.

End point values	Entire Study Population			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Subjects	32			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Time of consent up to 28 days after the last visit

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	No dictionary used
-----------------	--------------------

Dictionary version	N/A
--------------------	-----

Reporting groups

Reporting group title	Entire Study Population
-----------------------	-------------------------

Reporting group description:

Subject who had symptomatic transthyretin amyloidosis (ATTR) disease with documented Val30Met, Glu89Gln, Phe64Leu, Thr60Ala, Ser50Arg, Ile107Val, Val20Ile, Ile68Leu, or Val122Ile mutation in the TTR protein and were a part of THAOS were enrolled into this sub-study.

Serious adverse events	Entire Study Population		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 32 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Entire Study Population		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 32 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: This was a blood draw study in which no study drug was administered and there were no adverse events and no safety issues reported.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 August 2013	The protocol was updated to limit scope of blood collection for the purpose of development and validation of a biomarker assay and to remove the storage of samples for Biobanking, The amendment updated the sponsor name as FoldRx Pharmaceuticals, Inc had become a wholly-owned subsidiary of Pfizer, Inc. Pfizer protocol study number (B3461049) was inserted and protocol sections were renumbered to align with Pfizer protocol standards. Inclusion criteria and exclusion criteria were added to further clarify the substudy population. Language was added to clarify sample size determination and statistical analysis and to define study discontinuation criteria. There was a change in nomenclature whereby the term "patient" became "subject" and a change in the abbreviation ATTR-PN to TTR-FAP.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported